Log In
Print
BCIQ
Print
Print this Print this
 

OS2966

  Manage Alerts
Collapse Summary General Information
Company OncoSynergy Inc.
DescriptionHumanized mAb against integrin beta (1;CD29)
Molecular Target Integrin beta(1) (CD29)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat recurrent glioblastoma multiforme (GBM)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today